CD34 and acute myeloid leukemia: Another study detected a method for enhancing target therapy in AML by eradication of primitive CD34+ LSCs that have acquired aberrant glutathione metabolism using agents that target aberrant glutathione pathway such as parthenolide (PTL) or piperlongumine and/or piperlongumine (PLM) together with cytarabine and idarubicin on AML specimens.